玻璃体腔注射ziv-aflibercept治疗并延长方案的30个月结局
在新生血管性年龄相关性黄斑变性(nAMD)和糖尿病黄斑水肿(DMO)患眼中,中央黄斑厚度(CMT)显著下降,最佳矫正视力(BCVA)显著提高。TAE方案下注射次数随时间减少,药物在30个月内显示有效。
要点
- nAMD患眼30个月时CMT下降107.8 µm(p=0.012),BCVA提高0.52(p=0.001)。
- DMO患眼30个月时CMT下降224.3 µm(p=0.027),BCVA提高0.46(p=0.042)。
- 平均注射次数从第1年9.2次降至24-30个月间1.0次。
核心结论
- 采用TAE方案玻璃体腔注射ziv-aflibercept在30个月内对管理视网膜疾病显示有效。
研究设计与样本
- 前瞻性研究纳入连续接受玻璃体腔注射0.05 mL ziv-aflibercept(1.25 mg)治疗各种黄斑疾病的受试者。
主要发现
- nAMD患眼30个月随访时CMT下降107.8 µm(p=0.012),BCVA提高0.52(p=0.001)。
- DMO患眼30个月随访时CMT下降224.3 µm(p=0.027),BCVA提高0.46(p=0.042)。
- 所有疾病合并分析,第12个月平均注射次数为9.2次,12至18个月间为2.5次,18至24个月间为1.6次,24至30个月间为1.0次。
临床怎么用
- 对于nAMD和DMO患眼,可考虑采用TAE方案玻璃体腔注射ziv-aflibercept以改善解剖和视力结局。
- TAE方案下注射频率随时间延长而降低,需根据随访调整注射间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases. METHODS: In this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator. RESULTS: Fifty-three eyes of 48 subjects (33 naïve eyes) received intravitreal ziv-aflibercept and were followed between 12 and 30 months following TAE included neovascular age-related macular degeneration (nAMD) (35 eyes) and diabetic macular oedema (DMO) (18 eyes). In eyes with nAMD, CMT decreased by 107.8 µm at the 30-month follow-up (p=0.012) with BCVA gain of 0.52 (p=0.001). In eyes with DMO, CMT decreased by 224.3 µm at the 30-month follow-up (p=0.027) with BCVA gain of 0.46 (p=0.042). Combining all disease categories, the mean number of injections was 9.2 at month 12, 2.5 between 12 and 18 months, 1.6 between 18 and 24 months and 1.0 between 24 and 30 months. CONCLUSIONS: Using TAE regimen, intravitreal ziv-aflibercept appeared efficacious at managing retinal disease through month 30 using the TAE regimen.
引用
- Mansour AM, Charbaji A, Farah ME, et al. Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy. Br J Ophthalmol. 2018. PMID: 30072436. doi:10.1136/bjophthalmol-2018-312593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。